Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00839189 · ClinicalTrials.gov registry record · Phase 1

Effect of a 10,000 EU Dose of Endotoxin in Allergic and Mildly Asthmatic Adults

A Phase 1 study, sponsored by University of North Carolina, Chapel Hill.

Completed
Registry status
Phase 1
Development phase
11
Enrollment target

NCT00839189 is a Phase 1 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 11 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00839189, a Phase 1 study, has completed, sponsored by University of North Carolina, Chapel Hill.

COMPLETED
Registry status
Phase 1
Development phase
11 participants
Enrollment target

Study Summary

The purposes of this pilot safety study are to identify a dose of inhaled Clinical Center Reference Endotoxin (CCRE) that is well tolerated by allergic subjects that induces measurable increases in neutrophil content of induced sputum that can be employed to screen large populations for susceptibility to the inflammatory effect of inhaled endotoxin.

Interventions

  • BIOLOGICAL Clinical Center Reference Endotoxin (CCRE)

Trial Details

FieldValue
Enrollment Target 11 participants
Start Date 2002-10
Est. Completion 2006-06
Phase Phase 1

What the Registry Record Tells You About NCT00839189

The ClinicalTrials.gov registry entry for NCT00839189 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Clinical Center Reference Endotoxin (CCRE) is the first listed.

NCT00839189 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00839189 about?

NCT00839189 is a clinical study titled "Effect of a 10,000 EU Dose of Endotoxin in Allergic and Mildly Asthmatic Adults". The purposes of this pilot safety study are to identify a dose of inhaled Clinical Center Reference Endotoxin (CCRE) that is well tolerated by allergic subjects that induces measurable increases in neutrophil content of induced sputum that can be employed to screen large populations for susceptibili...

What is the current status of trial NCT00839189?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2002-10. Estimated completion is 2006-06.

What interventions are being tested in trial NCT00839189?

The interventions under investigation include: Clinical Center Reference Endotoxin (CCRE) (BIOLOGICAL).

Who is sponsoring clinical trial NCT00839189?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.